Table 5

Relapse outcomes in bipolar disorder treated prophylactically with carbamazepine or lithium

Trial
N
Duration in yearsOutcomeResult (carbamazepine compared with lithium)
Watkins 1987
N=37
UnclearAdditional time in remission3.3 months compared with 9.3 months; P<0.001
Lusznat 1988
N=54
1Relapse - hospitalization18.5% compared with 37%, NS
Coxhead 1992
N=31
1Relapse46% compared with 53%, NS
Denicoff 1997a
N=52
1Time to first manic episode66.2 days compared with 89.8 days; P=0.024
Simhandl 1993a
N=84
2Relapse - hospitalization36% compared with 14%, NS
Hartong 2003
N=94
2Relapse - as stated for (1) overall; (2) subgroup prophylactically randomized; (3) subgroup acutely randomized(1) 42% compared with 27%, NS
(2) 47% compared with 13%, P<0.05b
(3) 35% compared with 43%, NS
Greil 1997
N=144
2.5(1) Relapse - “hospitalization”
(2) Relapse - as stated (“recurrence”)
(1) 20% compared with 17%, NS
(2) 29% compared with 23%, NS
Placidi 1986a
N=83
3Relapse - as stated27.6% compared with 25.9%, NS
a

Excluded 33% to 58% of patients from analyses due to early discontinuation.

b

Calculated by the Oregon Evidence-based Practice Center using StatsDirect v2.7.0.

From: Results

Cover of Drug Class Review: Antiepileptic Drugs for Indications Other Than Epilepsy
Drug Class Review: Antiepileptic Drugs for Indications Other Than Epilepsy: Final Report Update 2 [Internet].
McDonagh M, Peterson K, Lee N, et al.
Portland (OR): Oregon Health & Science University; 2008 Oct.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.